Skip to content

Assessment of lymphoma involvement in bone marrow by a novel cell-based liquid biopsy platform from blood sampling

Assessment of lymphoma involvement in bone marrow by a novel cell-based liquid biopsy platform from blood sampling

Status
Unknown
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20220921002
Enrollment
176
Registered
2022-09-21
Start date
2022-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newly diagnosed lymphoma of any subtypes aged greater than 18 years. Newly diagnosed lymphoma of any subtypes and participants with normal white blood cell (WBC) counts and normal differential WBC counts from the last CBC result (within 1 year)

Interventions

Newly diagnosed lymphoma of any subtypes and participants with normal white blood cell (WBC) counts and normal differential WBC counts from the last CBC result (within 1 year) and aged greater than 18
Other
Newly diagnosed lymphoma of any subtypes aged greater than 18 years.

Sponsors

Siriraj Hospital Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed lymphoma of any subtypes 2. Aged greater than 18 years 3. Participants with normal white blood cell (WBC) counts and normal differential WBC counts from the last CBC result (within 1 year)

Exclusion criteria

Exclusion criteria: 1. Participants with known underlying diseases of hemolytic anemia 2. Participants with known underlying diseases of hematologic malignancy besides lymphoma 3. Participants with known underlying disease of neoplasms involving bone marrow 4. Participants with lymphocytosis (absolute lymphocyte count > 4,000/mcL) 5. Participants with a history of recently receiving blood transfusion within 4 weeks 6. Participants with a history of receiving chemotherapy within 4 weeks 7. Participants with a history of blood donation or recent blood loss greater than 250 mL within 4 weeks 8. Participants who receiving erythropoietin 9. Participants with GI mucosal involvement of lymphoma

Design outcomes

Primary

MeasureTime frame
To evaluate the correlation between circulating erythroblast event elevation and abnormality and confirmed BMI in lymphoma patients by BM study First clinic visit Result between circulating erythroblast event elevation and abnormality confirmed BMI per normal

Secondary

MeasureTime frame
To identify BMD specificity cut-off value to correctly predict BMI. within one year after end of study identify the optimal cut-off for highest test performance the classical receiver operator characteristic (ROC) curve analysis

Countries

Thailand

Contacts

Public Contactweerapat Owattanapanich

Division of Hematology ,Faculty of Medicine Siriraj Hospital, Mahidol University

weerapato36733@gmail.com0891081963

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026